Syncona to Acquire Applied Genetic Technologies Corporation

Syncona (via Bidco) Agrees to Acquire Freeline Therapeutics

February 12, 2024

Biotechnology

Syncona, through a wholly owned Bidco subsidiary, will acquire all remaining shares of Freeline Therapeutics for $6.50 per ADS in a take-private transaction. Freeline shareholders overwhelmingly approved the scheme; the deal is expected to become effective after UK court sanctioning and will result in Freeline delisting from Nasdaq to allow private development of its gene-therapy programs.

Novartis Acquires Gyroscope Therapeutics

December 22, 2021

Biotechnology

Novartis has agreed to acquire UK-based Gyroscope Therapeutics for $800 million upfront with up to $700 million in contingent milestone payments, adding GT005 — an AAV2-based, one-time investigational gene therapy for geographic atrophy secondary to AMD — and early-stage retinal assets to its ophthalmology pipeline. The transaction is subject to customary closing conditions and regulatory approvals; Gyroscope will continue to operate independently until closing.

AbCellera Acquires TetraGenetics

September 13, 2021

Biotechnology

AbCellera Biologics Inc. acquired TetraGenetics, Inc. in an all-cash transaction to integrate TetraGenetics' recombinant transmembrane protein expression platform into AbCellera's antibody discovery technology stack. The acquisition expands AbCellera's ability to generate antibodies against difficult-to-drug ion channels, GPCRs and other transmembrane targets, and includes upfront and milestone-based payments.

Lonza Group AG Acquires Synaffix B.V.

June 1, 2023

Biotechnology

Lonza Group AG has acquired Synaffix B.V., a Netherlands-based biotech company that commercialises a clinical-stage antibody-drug conjugate (ADC) technology platform. The deal brings Synaffix's ADC bioconjugation technology into Lonza's integrated ADC development and manufacturing offering to accelerate discovery, development, scale-up and commercialization of ADCs.

GTCR to Acquire Surmodics for $43.00 per Share; Equity Value Approximately $627M

May 29, 2024

Medical Devices

GTCR, a leading private equity firm, will acquire Surmodics, a Minnesota-based medical device and in vitro diagnostic technologies company, for $43.00 per share in cash, implying an approximate equity value of $627 million. The transaction, unanimously approved by Surmodics' board, is expected to close in the second half of 2024 and will take Surmodics private following customary regulatory and shareholder approvals.

Repligen Corporation Acquires ARTeSYN Biosolutions for $200M

October 28, 2020

Medical Devices

Repligen Corporation has agreed to acquire privately-held ARTeSYN Biosolutions for approximately $200 million (about $130 million cash and $70 million in Repligen stock). The purchase expands Repligen's single-use downstream bioprocessing systems portfolio — ARTeSYN was projected to generate roughly $30 million in pro forma 2020 revenue and the deal complements Repligen's recent EMT and NMS acquisitions.